Pfizer

METHOTREXATE

  1. Home
  2.  / 
  3. J Code
  4.  / METHOTREXATE – J9250

Manufacturer:

Pfizer

Name:

METHOTREXATE

HCPCS Code Descriptor:

Methotrexate sodium, 5 mg

Category:

J Code

HCPCS:

J9250

NDC(s):

00703-3671-01, 00703-3675-01, 00703-3678-01, 00703-3678-81, 16729-0277-03, 16729-0277-30, 16729-0277-35, 67457-0480-40, 67457-0466-10, 63323-0123-10, 63323-0122-59, 63323-0122-50, 61703-0408-25, 61703-0408-41, 61703-0350-38, 61703-0350-10, 61703-0124-40, 00143-9830-01, 00143-9519-10

Primary Type:

Oncology

Generic Status:

Multi-Source

Route of Administration:

Injection

About:

METHOTREXATE is an Oncology drug manufactured by Pfizer and administered via the Injection route of administration. The J Code: J9250 is aligned to the drug METHOTREXATE.

Methotrexate Sodium is a chemotherapy drug listed under the class of antimetabolites. This medication works by decreasing the growth of certain cells and slowing down the patient’s immune system. Methotrexate can be used to treat skin and joint disorders along with various types of cancer. This medication is administered via intramuscular injection, subcutaneous injection, and can even be administered orally. Methotrexate is a generic drug that is manufactured by Hikma pharmaceuticals, Sicor Pharmaceuticals, Accord Healthcare, Pfizer, Fresenius Kabi, Mylan, and others. There are many patient assistance websites for this medication.

Access Pricing and More By Registering

HCPCS Added Date:

1/1/94

HCPCS Effective Date:

1/1/97

HCPCS Short Description:

Methotrexate sodium inj

Billing and Coding Guide:

Not Found

Patient Assistance:

https://azuritysolutions.com/patients/xatmep/#product

https://www.rasuvo.com/patient-resources/